Documentos de Valenzuela-Silva C.M. | REDI

Regresar

Mostrando 3 resultados de: 3

Filtros aplicados

Área de conocimiento: "Cáncer"

Subtipo de publicación

Publisher

British Journal of Cancer(1)

Molecular and Cellular Biochemistry(1)

Área temáticas

Enfermedades(3)

Farmacología y terapéutica(3)

Ginecología, obstetricia, pediatría, geriatría(1)

Medicina y salud(1)

Área de conocimiento

Año de Publicación

Origen

Palabras Claves

B23/nucleophosmin(1)

Cancer targeted therapy(1)

Casein kinase 2(1)

Cervical Cancer(1)

CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo

Abstract: Protein Kinase CK2 is a serine-threonine kinase frequently deregulated in many human tumors. Here, w

Palabras claves:

apoptosis, Cancer targeted therapy, Casein kinase 2

Acevedo B.E., Alonso D.F., Ariosa J., Bacardí D.M., Baladron I., Besada-Pérez V., Betancourt L., Castellanos L.R., Cosme K., Cruz M., Díaz A., Falcón-Cama V., Farina H., Garay H.E., Gil J., Gómez D., Gómez R., González L.J., Hernández I., Herrera L., López C., López-Mola E., López-Saura P.A., Marcelo J.L., Mendoza O., Perea-Rodríguez S.E., Perera Y., Puchades Y., Reyes O., Rodriguez A., Sánchez A., Santana A., Serrano J.M., Sigman H., Silva R., Solares M., Thelvia I. Ramos Gómez, Valenzuela-Silva C.M.

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer

Abstract: Background:We conducted a phase 1 trial in patients with locally advanced cervical cancer by injecti

Palabras claves:

B23/nucleophosmin, Cervical Cancer, CIGB-300, tumour uptake

Acevedo B.E., Alonso D.F., Ancízar J.A., Baladron I., Casacó C.A., Coca M.A., García I., Gómez R., González L.J., González Y.M., Hernández I., I. Howland-Álvarez, López-Saura P.A., Martínez Y.M., Molina L., Perea-Rodríguez S.E., Perera A., Perera Y., Prats A., Reyes V., Solares M., Torres L.A., Valenzuela-Silva C.M.

Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies

Abstract: Background: Cervical cancer is now considered the second leading cause of death among women worldwid

Palabras claves:

Acevedo B.E., Alonso D.F., Baladron I., Castillo D., Díaz A., Gómez R., González C.A., Herrera L., López-Saura P.A., Perea-Rodríguez S.E., Santana A., Sigman H., Solares A.M., Thelvia I. Ramos Gómez, Valenzuela-Silva C.M.